Hepatic Transarterial Administrations of NKR-2 in Patients With Unresectable Liver Metastases From Colorectal Cancer

Summary

The purpose of this study is to test an experimental anti-cancer immunotherapy called NKR-2 (modified T cells), to treat colorectal cancer with unresectable liver metastases. The trial will test three dose levels (dose escalation). At each dose, the patients will receive three successive hepatic transarterial administrations, two weeks apart, of NKR-2 cells. The study will enroll up to 18 patients.

Timeline

Start

2017-10-11

Primary completion

2018-01-15

Completion

2018-12-15

Outcome

Outcome not reported

Stopped (Enrollment): “Difficulties in patient recruitment and clinical strategy modification based on new clinical data generated in the NKR-2 early development.”

Drugs

Indications